Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
- DOI
- 10.1016/j.omto.2023.08.006
- Published
- 2023 Sep 21
- Container
- Molecular therapy oncolytics
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.omto.2023.08.006,
title = {Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.},
author = {Loh AHP and Thura M and Gupta A and Tan SH and Kuan KKY and Ang KH and Merchant K and Chang KTE and Yon HY and Chen Y and Cheng MHW and Mahadev A and Ng MCH and Seng MS and Iyer P and Chia PL and Soh SY and Zeng Q},
year = {2023},
journal = {Molecular therapy oncolytics},
doi = {10.1016/j.omto.2023.08.006},
url = {https://doi.org/10.1016/j.omto.2023.08.006}
}RIS
TY - JOUR TI - Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody. AU - Loh AHP AU - Thura M AU - Gupta A AU - Tan SH AU - Kuan KKY AU - Ang KH AU - Merchant K AU - Chang KTE AU - Yon HY AU - Chen Y AU - Cheng MHW AU - Mahadev A AU - Ng MCH AU - Seng MS AU - Iyer P AU - Chia PL AU - Soh SY AU - Zeng Q PY - 2023 JO - Molecular therapy oncolytics DO - 10.1016/j.omto.2023.08.006 UR - https://doi.org/10.1016/j.omto.2023.08.006 ER -
APA
AHP, L., M, T., A, G., SH, T., KKY, K., KH, A., K, M., KTE, C., HY, Y., Y, C., MHW, C., A, M., MCH, N., MS, S., P, I., PL, C., SY, S., & Q, Z. (2023). Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.. Molecular therapy oncolytics. https://doi.org/10.1016/j.omto.2023.08.006
Source records
- pubmed · retrieved 2026-09-25T06:05:04.997Z